All In Biotech

Drug Trial Radar · NCT03524118

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

Last checked: Nov 20, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

Sep 20, 2018

Primary completion

Sep 14, 2022

Study completion Sep 14, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 weeks, up to 8 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at \>35 weeks gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel prior to administering the next-highest dose.

Conditions

  • Respiratory Tract Infection
  • Respiratory Syncytial Virus

Interventions

  • ClesrovimabDrug

    Single ascending doses of clesrovimab will be administered via IM injection.

  • PlaceboDrug

    Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced At Least One Solicited Injection Site Adverse Event (AE)Time frame: Up to Day 5
  2. Percentage of Participants Who Experienced At Least One Solicited Systemic Adverse Event (AE)Time frame: Up to Day 5
  3. Percentage of Participants Who Experienced At Least One Serious Adverse Event (SAE)Time frame: Up to Day 545

Locations

34 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital - Colorado ( Site 0067)

    Aurora, Colorado

  • Next Phase Research Alliance, LLC ( Site 0075)

    Homestead, Florida

  • Acevedo Clinical Research Associates ( Site 0025)

    Miami, Florida

  • Kapiolani Medical Center for Women and Children ( Site 0027)

    Honolulu, Hawaii

  • Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0081)

    Topeka, Kansas

  • Children's Mercy Hospital ( Site 0037)

    Kansas City, Missouri

  • Dartmouth-Hitchcock Medical Center ( Site 0032)

    Lebanon, New Hampshire

  • SUNY Upstate Medical University Hospital ( Site 0029)

    Syracuse, New York

  • WakeMed Health and Hospitals ( Site 0033)

    Raleigh, North Carolina

  • Cincinnati Children's Hospital Medical Center ( Site 0031)

    Cincinnati, Ohio

  • Ohio Pediatric Research Association ( Site 0066)

    Dayton, Ohio

  • Coastal Pediatric Research ( Site 0028)

    Charleston, South Carolina

  • Tribe Clinical Research, LLC ( Site 0082)

    Greenville, South Carolina

  • University of Texas Medical Branch at Galveston ( Site 0039)

    Galveston, Texas

  • Tekton Research, Inc. ( Site 0026)

    San Antonio, Texas

  • Multicare Institute For Research And Innovation ( Site 0035)

    Tacoma, Washington

  • University of Wisconsin American Family Children's Hospital ( Site 0068)

    Madison, Wisconsin

  • Centro de Investigacion Clinica Bradford Hill ( Site 0103)

    Santiago, Region M. de Santiago, Chile

  • Hospital La Florida ( Site 0050)

    Santiago, Region M. de Santiago, Chile

  • Facultad Medicina Universidad de Chile ( Site 0104)

    Santiago, Region M. de Santiago, Chile

  • Hospital Padre Hurtado ( Site 0102)

    Santiago, Region M. de Santiago, Chile

  • Fundacion Hospital San Vicente de Paul ( Site 0097)

    Medellín, Antioquia, Colombia

  • Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0098)

    Medellín, Antioquia, Colombia

  • MedPlus Medicina Prepagada S.A. ( Site 0095)

    Bogotá, Bogota D.C., Colombia

  • Fundacion Universitaria de Ciencias de la Salud - Sociedad de Cirugia ( Site 0099)

    Bogotá, Bogota D.C., Colombia

  • Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0100)

    Chía, Cundinamarca, Colombia

  • Fundacion Valle del Lili ( Site 0090)

    Cali, Valle del Cauca Department, Colombia

  • Chris Hani Baragwanath Academic Hospital ( Site 0262)

    Johannesburg, Gauteng, South Africa

  • Tygerberg Hospital ( Site 0261)

    Cape Town, Western Cape, South Africa

  • Seoul National University Hospital ( Site 0071)

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System ( Site 0073)

    Seoul, South Korea

  • Samsung Medical Center ( Site 0072)

    Seoul, South Korea

  • Hospital Universitario La Paz ( Site 0242)

    Madrid, Spain

  • Hospital Clinico Universitario de Santiago ( Site 0241)

    Santiago de Compostela, La Coruna, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.